JP5922018B2 - Muc1抗体 - Google Patents

Muc1抗体 Download PDF

Info

Publication number
JP5922018B2
JP5922018B2 JP2012522029A JP2012522029A JP5922018B2 JP 5922018 B2 JP5922018 B2 JP 5922018B2 JP 2012522029 A JP2012522029 A JP 2012522029A JP 2012522029 A JP2012522029 A JP 2012522029A JP 5922018 B2 JP5922018 B2 JP 5922018B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
cancer
derivative
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012522029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500703A5 (cg-RX-API-DMAC7.html
JP2013500703A (ja
Inventor
シュテファン ゴレツ,
シュテファン ゴレツ,
アンチェ ダニエルチク,
アンチェ ダニエルチク,
レナテ シュタン,
レナテ シュタン,
ウヴェ カルステン,
ウヴェ カルステン,
Original Assignee
グリコトープ ゲーエムベーハー
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコトープ ゲーエムベーハー, グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2013500703A publication Critical patent/JP2013500703A/ja
Publication of JP2013500703A5 publication Critical patent/JP2013500703A5/ja
Application granted granted Critical
Publication of JP5922018B2 publication Critical patent/JP5922018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012522029A 2009-07-31 2010-07-30 Muc1抗体 Active JP5922018B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942.5 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
US61/230,211 2009-07-31
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000133A Division JP6272916B2 (ja) 2009-07-31 2016-01-04 Muc1抗体

Publications (3)

Publication Number Publication Date
JP2013500703A JP2013500703A (ja) 2013-01-10
JP2013500703A5 JP2013500703A5 (cg-RX-API-DMAC7.html) 2013-09-05
JP5922018B2 true JP5922018B2 (ja) 2016-05-24

Family

ID=41460131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012522029A Active JP5922018B2 (ja) 2009-07-31 2010-07-30 Muc1抗体
JP2016000133A Active JP6272916B2 (ja) 2009-07-31 2016-01-04 Muc1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016000133A Active JP6272916B2 (ja) 2009-07-31 2016-01-04 Muc1抗体

Country Status (17)

Country Link
US (1) US9217038B2 (cg-RX-API-DMAC7.html)
EP (3) EP2281844A1 (cg-RX-API-DMAC7.html)
JP (2) JP5922018B2 (cg-RX-API-DMAC7.html)
KR (1) KR101773506B1 (cg-RX-API-DMAC7.html)
CN (1) CN102574926B (cg-RX-API-DMAC7.html)
AR (1) AR077334A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010278302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012002226A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768888C (cg-RX-API-DMAC7.html)
CU (1) CU23972B1 (cg-RX-API-DMAC7.html)
EA (1) EA029954B1 (cg-RX-API-DMAC7.html)
IL (1) IL217827A (cg-RX-API-DMAC7.html)
MX (1) MX2012000874A (cg-RX-API-DMAC7.html)
NZ (1) NZ597563A (cg-RX-API-DMAC7.html)
SG (2) SG177527A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011012309A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200166B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2603528B1 (en) 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CN105008550B (zh) * 2013-03-01 2018-03-30 学校法人埼玉医科大学 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015119180A1 (ja) * 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン4(muc4)糖ペプチドに対する抗体及びその用途
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗muc1抗体又はその抗原結合性断片及びその用途
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトMUC1抗体Fabフラグメント
JP7162011B2 (ja) * 2017-01-18 2022-10-27 ナノクルーズ・ファーマシューティカル・リミテッド 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
CN110382541A (zh) 2017-03-29 2019-10-25 葛莱高托普有限公司 人源化抗cd40抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
KR102832078B1 (ko) * 2017-10-24 2025-07-08 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc1抗体およびその使用
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗muc1抗體-藥物結合物投予的藥劑低敏感性癌之治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1993020841A1 (en) 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Muc−1抗原に対する治療用抗体およびその使用方法
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
DK1654353T3 (da) 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Also Published As

Publication number Publication date
CN102574926B (zh) 2014-10-15
IL217827A0 (en) 2012-03-29
KR20120051724A (ko) 2012-05-22
CA2768888A1 (en) 2011-02-03
US20120128676A1 (en) 2012-05-24
EP2281844A1 (en) 2011-02-09
AU2010278302A1 (en) 2012-02-09
IL217827A (en) 2017-05-29
SG10201404019XA (en) 2014-09-26
NZ597563A (en) 2013-08-30
SG177527A1 (en) 2012-02-28
EP3421497A1 (en) 2019-01-02
EA201270207A1 (ru) 2012-07-30
AR077334A1 (es) 2011-08-17
WO2011012309A8 (en) 2011-04-07
MX2012000874A (es) 2012-02-01
JP2016041771A (ja) 2016-03-31
CU20120019A7 (es) 2012-06-21
BR112012002226A2 (pt) 2016-11-08
JP6272916B2 (ja) 2018-01-31
WO2011012309A1 (en) 2011-02-03
CU23972B1 (es) 2013-12-27
CN102574926A (zh) 2012-07-11
KR101773506B1 (ko) 2017-08-31
AU2010278302B2 (en) 2014-12-18
ZA201200166B (en) 2013-03-27
US9217038B2 (en) 2015-12-22
JP2013500703A (ja) 2013-01-10
EP2459595A1 (en) 2012-06-06
EA029954B1 (ru) 2018-06-29
CA2768888C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
JP6272916B2 (ja) Muc1抗体
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
AU2001249760B2 (en) Mucin-1 specific binding members and methods of use thereof
EP4083072B1 (en) Muc1* antibodies
TWI777056B (zh) 結合至ssea4的單株抗體及其用途
EP4289862A1 (en) Anti-human b7-h3 antibody and application thereof
CN112449641A (zh) 抗-muc1抗体
CN103025760A (zh) 人源化egfr抗体
WO2018166507A1 (zh) 新型重组双功能融合蛋白及其制备方法和用途
JP7828286B2 (ja) 抗muc1-sea抗体
JP2022527761A (ja) がん治療のための多重特異性作用物質
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
TW201945033A (zh) 抗糖皮質激素誘導的腫瘤壞死因子受體(gitr)的小型化抗體、其聚合物及應用
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
JP7313730B2 (ja) エンドセリン受容体a結合力が向上した抗体
CN117843793B (zh) 抗间皮素抗体、抗原结合片段及其用途
HK40082756A (en) Muc1* antibodies
CN118165119A (zh) 包含IL-15/IL-15Rα复合物的重组蛋白及其用途
JP2024544961A (ja) 抗cldn18.2モノクローナル抗体およびその使用
HK40054516B (en) Novel mesothelin antibody and composition comprising the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160413

R150 Certificate of patent or registration of utility model

Ref document number: 5922018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250